Related references
Note: Only part of the references are listed.Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
Matteo Bassetti et al.
CLINICAL INFECTIOUS DISEASES (2019)
Profile of a Novel Anionic FluoroquinoloneDelafloxacin
Paul M. Tulkens et al.
CLINICAL INFECTIOUS DISEASES (2019)
Current Treatment Options for Acute Skin and Skin-structure Infections
Yoav Golan
CLINICAL INFECTIOUS DISEASES (2019)
Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
Philip A. Giordano et al.
CLINICAL INFECTIOUS DISEASES (2019)
The safety of treatment options for acute bacterial skin and skin structure infections
Matteo Bassetti et al.
EXPERT OPINION ON DRUG SAFETY (2019)
In Vivo Pharmacodynamic Target Determination for Delafloxacin against Klebsiella pneumoniae and Pseudomonas aeruginosa in the Neutropenic Murine Pneumonia Model
Miao Zhao et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Novel developments in the treatment of acute bacterial skin and skin structure infections
Rupal K. Jaffa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2019)
470. Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in Patients with Significant Drug Abuse: Outcomes from Global Phase 3 Studies of Delafloxacin (DLX)
J Scott Overcash et al.
Open Forum Infectious Diseases (2019)
Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
Randall K. Hoover et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study
William O'Riordan et al.
CLINICAL INFECTIOUS DISEASES (2018)
Clinical review of delafloxacin: a novel anionic fluoroquinolone
Bryan T. Mogle et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Clinical Pharmacokinetics of Sulfobutylether-β-Cyclodextrin in Patients With Varying Degrees of Renal Impairment
Randall K. Hoover et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Pharmacokinetics of Intravenous Delafloxacin in Patients With End-Stage Renal Disease
Randall Hoover et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin
R. S. Dawe et al.
PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES (2018)
Safety of Delafloxacin: Focus on Adverse Events of Special Interest
Thomas Lodise et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
2018 WSES/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections
Massimo Sartelli et al.
WORLD JOURNAL OF EMERGENCY SURGERY (2018)
2377. Outcomes in Patients With History of Cardiac or Vascular Disease (CV) During Treatment of Acute Bacterial Skin And Skin Structure Infection (ABSSSI) With Delafloxacin (DLX) vs. Vancomycin/Aztreonam (VAN/AZ)
Godson Oguchi et al.
Open Forum Infectious Diseases (2018)
Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties
Sarah C. J. Jorgensen et al.
INFECTIOUS DISEASES AND THERAPY (2018)
Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
Randall Hoover et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections
Matteo Bassetti et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study
J. Pullman et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections
S. McCurdy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin
Susan K. Paulson et al.
CLINICAL THERAPEUTICS (2017)
In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
M. A. Pfaller et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin
Jeff Kingsley et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
In Vitro Activity of Delafloxacin Tested against Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis
Robert K. Flamm et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age
Randall Hoover et al.
CLINICAL THERAPEUTICS (2016)
Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers
Randall Hoover et al.
CLINICAL THERAPEUTICS (2016)
Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin
Bela Kocsis et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2016)
A Thorough QT Study To Evaluate the Effects of Therapeutic and Supratherapeutic Doses of Delafloxacin on Cardiac Repolarization
Jeffrey S. Litwin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy
Francoise Van Bambeke
FUTURE MICROBIOLOGY (2015)
A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections
William O'Riordan et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2015)
Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration
Andrew McEwen et al.
XENOBIOTICA (2015)
Comparison of the Antibiotic Activities of Daptomycin, Vancomycin, and the Investigational Fluoroquinolone Delafloxacin against Biofilms from Staphylococcus aureus Clinical Isolates
Wafi Siala et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Executive Summary: Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America
Dennis L. Stevens et al.
CLINICAL INFECTIOUS DISEASES (2014)
A Combined Pharmacodynamic Quantitative and Qualitative Model Reveals the Potent Activity of Daptomycin and Delafloxacin against Staphylococcus aureus Biofilms
Julia Bauer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization
Joan M. Remy et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
New findings on the structure-phototoxicity relationship and photostability of fluoroquinolones with various substituents at position 1
N Hayashi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against gram-positive and gram-negative organisms
LS Almer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone
AM Nilius et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Share Paper
